Traws Pharma, INC Form 4 insider transactions

Traws Pharma Director John Leaman was granted 15,609 stock options with a $1.89 exercise price, vesting over three years.

Traws Pharma, Inc. Director Trafford Clarke has acquired 23,000 stock options with an exercise price of $1.65, vesting fully on June 19, 2026.

Traws Pharma, Inc. Director Jack E. Stover reported the acquisition of 23,000 stock options with an exercise price of $1.65 per share, set to vest on June 19, 2026.

Traws Pharma, Inc. Director Mary Teresa Shoemaker has been granted 23,000 stock options with an exercise price of $1.65 per share, vesting on the first anniversary of the grant date.

Traws Pharma, Inc. Director Werner Cautreels was granted 23,000 stock options with an exercise price of $1.65, vesting fully on June 19, 2026.

TPAV, LLC distributed its holdings of Traws Pharma common stock and Series C preferred stock to its members, including Nikolay Savchuk, ceasing to be a 10% owner.

Werner Cautreels, CEO of Traws Pharma, exercised pre-funded warrants to acquire 96,348 shares of common stock at $0.01 per share.

Mark Patrick Guerin, CFO of Traws Pharma, Inc., resigned effective February 5, 2025, and will no longer be subject to Section 16 reporting requirements.

OrbiMed Advisors LLC and related entities acquired pre-funded and Series A warrants in Traws Pharma, Inc. on December 29, 2024.

Traws Pharma's CEO, Werner Cautreels, acquired pre-funded and Series A warrants as part of a Class B Unit purchase.

TPAV, LLC, a 10% owner of Traws Pharma, Inc., acquired pre-funded and Series A warrants as part of a Class B Unit purchase.

Traws Pharma's Chief Operating Officer, Nikolay Savchuk, acquired pre-funded and Series A warrants through TPAV, LLC, a company he manages.

Director Luba Greenwood acquired stock options in Traws Pharma, Inc. on September 16, 2024.

Iain D. Dukes, Executive Chairman of Traws Pharma, files an amended Form 4 to correct a minor error in the reported number of shares underlying restricted stock units.

Nikolay Savchuk, COO of Traws Pharma, files an amended Form 4 to correct a minor error in the reported number of restricted stock units granted.

Mark Guerin, CFO of Traws Pharma, reports the vesting of restricted stock units and subsequent tax withholding.

Robert Redfield, Acting Chief Medical Officer of Traws Pharma, Inc., reports the acquisition of 97,500 restricted stock units.

Charles David Pauza, Chief Science Officer of Traws Pharma, reports the acquisition of stock options and restricted stock units as a result of the merger with Trawsfynydd Therapeutics, Inc.

Werner Cautreels, CEO of Traws Pharma, reports the acquisition of 200,000 restricted stock units that vest annually starting April 1, 2025.

Nikolay Savchuk, Chief Operating Officer of Traws Pharma, reports acquisition-related transactions including stock and option awards following the merger with Trawsfynydd Therapeutics.

Executive Chairman Iain D. Dukes reports acquisition of common stock, restricted stock units, and stock options in Traws Pharma following the merger with Trawsfynydd Therapeutics.

Mark Guerin, CFO and COO of Onconova Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

CEO Steven Fruchtman reports the vesting and disposal of Onconova Therapeutics (ONTX) restricted stock units and common stock.